首页> 外文期刊>Cancer biology & therapy >iTRAQ-based quantitative proteomic analysis of differentially expressed proteins in chemoresistant nasopharyngeal carcinoma
【24h】

iTRAQ-based quantitative proteomic analysis of differentially expressed proteins in chemoresistant nasopharyngeal carcinoma

机译:基于ITRAQ在化学鼻咽癌中的差异表达蛋白的定量蛋白质组学分析

获取原文
获取原文并翻译 | 示例
       

摘要

Nasopharyngeal carcinoma (NPC) is a highly prevalent disease in Southeast Asia. The disease is typically diagnosed in the later stages, and chemotherapy resistance often causes treatment failure. To investigate the underlying mechanisms of drug resistance, we searched for chemoresistant-associated proteins in NPC and drug-resistant NPC cell lines using isobaric tags for relative and absolute quantitation combined with nano liquid chromatography-tandem mass spectrometry. The chemoresistant NPC cell lines CNE1DDP and CNE2DDP were resistant to 1mg/L cisplatin, had resistant indexes of 4.58 and 2.63, respectively, and clearly grew more slowly than the NPC cell lines CNE1 and CNE2. Using three technical replicates, we identified 690 nonredundant proteins, 56 of which were differentially expressed in both groups of cell lines (CNE1 vs. CNE1DDP and CNE2 vs. CNE2DDP). Gene Ontology, KEGG pathway, and miRNA analyses and protein-protein interactions of differentially expressed proteins showed that proteins TRIM29, HSPB1, CLIC1, ANXA1, and STMN1, among others, may play a role in the mechanisms of chemoresistance in clinical therapy. The chemotherapy-resistant proteomic profiles obtained may allow the identification of novel biomarkers for early detection of chemoresistance in NPC and other cancers.
机译:鼻咽癌(NPC)是东南亚的普遍普遍疫苗。该疾病通常被诊断为在后期阶段,化疗抗性通常导致治疗失败。为了研究耐药性的潜在机制,我们在NPC和耐药性NPC细胞中搜索了Chemolateistant相关的蛋白,使用同位数标签用于相对和绝对定量,与纳米液相色谱 - 串联质谱法联合。 Chemolateistant NPC细胞系CNE1DDP和CNE2DDP耐含1mg / L顺铂,分别具有4.58和2.63的耐药指数,并且显然比NPC细胞系CNE1和CNE2更缓慢。使用三种技术复制,我们鉴定了690个非冗余蛋白,其中56个在两组细胞系(CNE1与CNE1DDP和CNE2对CNE2DDP)中差异表达。差异表达蛋白质的基因本体,Kegg途径和MiRNA分析和蛋白质 - 蛋白质 - 蛋白质 - 蛋白质 - 蛋白质 - 蛋白质 - 蛋白质 - 蛋白质 - 蛋白质汤姆,HspB1,Clic1,AnxA1和STMN1等,其中可能在临床疗法中的化学机制中起作用。所获得的化疗抗性蛋白质组学谱可以允许鉴定新型生物标志物,用于早期检测NPC和其他癌症的化学抑制。

著录项

  • 来源
    《Cancer biology & therapy》 |2018年第9期|共16页
  • 作者单位

    Cent S Univ Xiangya Hosp Dept Clin Lab Changsha 410008 Hunan Peoples R China;

    Cent S Univ Xiangya Hosp Dept Clin Lab Changsha 410008 Hunan Peoples R China;

    Cent S Univ Xiangya Hosp Dept Clin Lab Changsha 410008 Hunan Peoples R China;

    Cent S Univ Xiangya Hosp Dept Clin Lab Changsha 410008 Hunan Peoples R China;

    Cent S Univ Xiangya Hosp Dept Clin Lab Changsha 410008 Hunan Peoples R China;

    Cent S Univ Xiangya Hosp Dept Clin Lab Changsha 410008 Hunan Peoples R China;

    Cent S Univ Xiangya Hosp Dept Clin Lab Changsha 410008 Hunan Peoples R China;

    Cent S Univ Xiangya Hosp Dept Clin Lab Changsha 410008 Hunan Peoples R China;

    Cent S Univ Xiangya Hosp Dept Clin Lab Changsha 410008 Hunan Peoples R China;

    Cent S Univ Xiangya Hosp Higher Educ Key Lab Canc Prote &

    Translat Med Hun Changsha Hunan;

    Cent S Univ Xiangya Hosp Dept Pathol Changsha Hunan Peoples R China;

    Cent S Univ Xiangya Hosp Dept Clin Lab Changsha 410008 Hunan Peoples R China;

    Cent S Univ Xiangya Hosp Dept Clin Lab Changsha 410008 Hunan Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学;
  • 关键词

    iTRAQ; nasopharyngeal carcinoma; chemoresistance; bioinformatics; proteomic profiles; ANXA1; TRIM29;

    机译:ITRAQ;鼻咽癌;化学态;生物信息学;蛋白质组学曲线;ANXA1;TRIM29;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号